Features
Generative AI design of novel enzyme sequences
Ultra-high-throughput screening (1000-fold more variants)
Multi-property optimization (activity, stability, manufacturability)
Proprietary engineered enzymes for molecular biology
Custom enzyme engineering services
AI models fine-tuned on internal screening data
75% faster enzyme development vs. traditional methods
80% lower screening costs compared to traditional methods
Rapid iteration across millions of variants
Industrial-grade enzyme delivery
Contact-based project initiation
Predictive AI models for protein-ligand interactions
Generative AI for novel molecule design
Built on Nobel Prize-winning AlphaFold system
Drug Design Engine combining predictive and generative AI
Digital biology simulation at scale
Interdisciplinary team of ML and pharma experts
Rapid iteration through AI-driven drug design engine
Partnership model for large-scale drug development
Collaboration with Novartis and Johnson & Johnson
US operations established in 2025
Series B funding in February 2026
